Karachi: Liven Pharma Limited has officially submitted its final offer document to the Securities and Exchange Commission of Pakistan (SECP) as part of its ongoing right issue process, marking a significant step in the company's capital-raising strategy. The submission follows the initial announcement made on September 12, 2025, regarding the issuance of right shares on the Pakistan Stock Exchange (PSX).
The final offer document, submitted on October 2, 2025, includes a comprehensive undertaking by the company's Chief Executive Officer, Kashif Hussain Siddiqui, and Chief Financial Officer, Muhammad Shah. The undertaking certifies that the document contains all material information about the issuer and the issue, with no concealment of pertinent details. It also confirms that the opinions and intentions expressed within are honestly held and that the document complies with all applicable regulations under the Companies Act, 2017, and the Companies (Further Issue of Shares) Regulations, 2020.
According to information available from the Pakistan Stock Exchange (PSX), Liven Pharma Limited plans to offer 20,000,000 right shares at a price of PKR 10 per share. This represents 21.496% of the existing paid-up capital of the company. The issue aims to provide existing shareholders the opportunity to subscribe to additional shares in proportion to their current holdings.
The Board of Directors has further confirmed that all material information required under relevant legislative frameworks has been disclosed. They emphasized that the right issue is at the discretion of the board and does not require approval from either the SECP or the securities exchange.
The underwriter for this right issue is Dawood Equities Limited, with an underwriting commitment of PKR 166,000,000. Major shareholders, including Atif Hussain Siddiqui and Kashif Hussain Siddiquie, have committed to subscribing to a total of 3,478,780 shares, amounting to PKR 34,787,800. This commitment will adjust their shareholding from 86.97% pre-issuance to 74.66% post-issuance.
The board has also resolved that any fractional rights shares will be consolidated under the Company Secretary's name and sold on the PSX, with net proceeds distributed to entitled shareholders according to their entitlements.
The designated market category for this right issue is the pharmaceutical sector, where Liven Pharma Limited continues to operate and expand its footprint.